Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma [PDF]
Biomarker Research, 2022 AbstractPatients with relapsed/refractory early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) respond poorly to traditional therapy and have dismal prognosis. CD7 is a promising therapeutic targets for chimeric antigen receptor modified T cell therapy (CART) due to its widely expression in almost all T-cell malignancies.
Haiping Dai +9 more
openalex +4 more sources
Gene expression profiling of precursor T-cell lymphoblastic leukemia/lymphoma identifies oncogenic pathways that are potential therapeutic targets [PDF]
Leukemia, 2007 We compared the gene expression pattern of thymic tumors from precursor T-cell lymphoblastic lymphoma/leukemia (pre-T LBL) that arose in transgenic mice that overexpressed SCL, LMO1 or NUP98-HOXD13 (NHD13) with that of thymocytes from normal littermates.
Y-W Lin, PD Aplan
openalex +5 more sources
An unusual presentation of precursor T cell lymphoblastic leukemia/lymphoma with cholestatic jaundice: case report [PDF]
Journal of Hematology & Oncology, 2009 Cholestatic jaundice as a presenting symptom of Precursor T-lymphoblastic leukemia (T-ALL)/lymphoma (T-LBL) has never been reported in literature. Similarly, precursor T-ALL/T-LBL is characteristically negative for synaptophysin. We report the first case of a patient with precursor T-ALL/T-LBL who presented with cholestatic jaundice and aberrant tumor ...
Kevin Patel +2 more
openalex +6 more sources
A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma [PDF]
Blood, 2009 Abstract The serine/threonine Pim kinases are up-regulated in specific hematologic neoplasms, and play an important role in key signal transduction pathways, including those regulated by MYC, MYCN, FLT3-ITD, BCR-ABL, HOXA9, and EWS fusions.
Ying-Wei Lin +10 more
openalex +6 more sources
Signal Pathway in Precursor B-Cell Lymphoblastic Leukemia/Lymphoma
, 2017 Tatsuaki Tsuruyama, Takuya Hiratsuka
openalex +5 more sources
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype [PDF]
Blood, 2016 Key Points Adult patients with ETP-ALL/LBL have poor long-term outcomes. Novel therapies are urgently needed for adult patients with ETP-ALL/LBL.
Nitin Jain +16 more
openalex +4 more sources
Blood, 2021 Abstract Patients with relapsed/refractory early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) respond poorly to traditional therapy and have dismal prognosis. CD7 expresses in almost all blasts of T-cell lymphoma/leukemia and represents one of the most promising therapeutic targets for T-ALL/LBL by CD7 targeted chimeric
Haiping Dai +7 more
openalex +3 more sources
Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Date of authorisation: 23/11/2015, Revision: 9, Status: Authorised [PDF]
Case Medical Research, 2019 +5 more sources
Human medicines European public assessment report (EPAR): Spectrila, asparaginase, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Date of authorisation: 14/01/2016, Revision: 3, Status: Authorised [PDF]
Case Medical Research, 2019 openalex +2 more sources